Health Sciences Acquisitions Co. 2 (HSAQ) Competitors $2.58 -0.27 (-9.47%) As of 04/24/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock HSAQ vs. LUCD, OBIO, INFU, KRMD, SKIN, MGRM, ICAD, NSPR, MBOT, and SRTSShould you be buying Health Sciences Acquisitions Co. 2 stock or one of its competitors? The main competitors of Health Sciences Acquisitions Co. 2 include Lucid Diagnostics (LUCD), Orchestra BioMed (OBIO), InfuSystem (INFU), KORU Medical Systems (KRMD), Beauty Health (SKIN), Monogram Orthopaedics (MGRM), iCAD (ICAD), InspireMD (NSPR), Microbot Medical (MBOT), and Sensus Healthcare (SRTS). These companies are all part of the "surgical & medical instruments" industry. Health Sciences Acquisitions Co. 2 vs. Lucid Diagnostics Orchestra BioMed InfuSystem KORU Medical Systems Beauty Health Monogram Orthopaedics iCAD InspireMD Microbot Medical Sensus Healthcare Lucid Diagnostics (NASDAQ:LUCD) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk, community ranking and valuation. Do institutionals & insiders hold more shares of LUCD or HSAQ? 74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. 8.8% of Lucid Diagnostics shares are held by company insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend LUCD or HSAQ? Lucid Diagnostics currently has a consensus price target of $3.50, suggesting a potential upside of 163.16%. Given Lucid Diagnostics' stronger consensus rating and higher probable upside, research analysts plainly believe Lucid Diagnostics is more favorable than Health Sciences Acquisitions Co. 2.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lucid Diagnostics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Health Sciences Acquisitions Co. 2 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in LUCD or HSAQ? Lucid Diagnostics received 40 more outperform votes than Health Sciences Acquisitions Co. 2 when rated by MarketBeat users. CompanyUnderperformOutperformLucid DiagnosticsOutperform Votes4068.97% Underperform Votes1831.03% Health Sciences Acquisitions Co. 2N/AN/A Which has better earnings and valuation, LUCD or HSAQ? Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Lucid Diagnostics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLucid Diagnostics$4.35M27.77-$52.67M-$1.08-1.23Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A Is LUCD or HSAQ more profitable? Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -1,069.87%. Company Net Margins Return on Equity Return on Assets Lucid Diagnostics-1,069.87% N/A -123.54% Health Sciences Acquisitions Co. 2 N/A N/A -2.38% Does the media favor LUCD or HSAQ? In the previous week, Lucid Diagnostics had 8 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 8 mentions for Lucid Diagnostics and 0 mentions for Health Sciences Acquisitions Co. 2. Lucid Diagnostics' average media sentiment score of 0.68 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that Lucid Diagnostics is being referred to more favorably in the media. Company Overall Sentiment Lucid Diagnostics Positive Health Sciences Acquisitions Co. 2 Neutral Which has more risk and volatility, LUCD or HSAQ? Lucid Diagnostics has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, suggesting that its stock price is 91% less volatile than the S&P 500. SummaryLucid Diagnostics beats Health Sciences Acquisitions Co. 2 on 9 of the 14 factors compared between the two stocks. Get Health Sciences Acquisitions Co. 2 News Delivered to You Automatically Sign up to receive the latest news and ratings for HSAQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HSAQ vs. The Competition Export to ExcelMetricHealth Sciences Acquisitions Co. 2Surgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.93M$4.29B$5.44B$7.81BDividend YieldN/A46.48%5.44%4.30%P/E RatioN/A30.2922.1418.36Price / SalesN/A52.50389.71101.37Price / CashN/A51.0838.2034.62Price / Book-4.166.096.664.18Net Income-$380,000.00$67.60M$3.21B$247.71M7 Day Performance-9.47%4.55%5.83%6.45%1 Month Performance-42.79%-8.34%-4.31%-3.14%1 Year Performance-41.89%29.06%17.83%5.40% Health Sciences Acquisitions Co. 2 Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HSAQHealth Sciences Acquisitions Co. 2N/A$2.58-9.5%N/A-36.4%$28.93MN/A0.004LUCDLucid Diagnostics2.4532 of 5 stars$1.20-0.8%$3.50+191.7%+94.7%$108.91M$4.35M-1.0570News CoveragePositive NewsOBIOOrchestra BioMed1.7026 of 5 stars$2.84-0.4%$15.00+428.2%-42.4%$108.81M$2.64M-1.764Analyst ForecastGap UpINFUInfuSystem2.0028 of 5 stars$4.91flat$13.00+164.8%N/A$103.19M$134.86M81.85410KRMDKORU Medical Systems2.4712 of 5 stars$2.24-1.3%$4.70+109.8%+13.2%$102.94M$33.65M-8.9680News CoverageGap UpSKINBeauty Health1.8501 of 5 stars$0.82-2.9%$2.50+204.4%-68.9%$102.86M$334.29M-1.961,030Positive NewsMGRMMonogram Orthopaedics2.2522 of 5 stars$2.65-1.9%$5.40+103.8%+22.7%$93.52M$364,999.00-5.6428ICADiCAD0.415 of 5 stars$3.03-5.9%N/A+111.5%$82.92M$19.61M-23.31140Gap UpHigh Trading VolumeNSPRInspireMD1.6115 of 5 stars$2.60+0.4%$4.75+82.7%+40.5%$79.65M$7.01M-3.4750News CoverageMBOTMicrobot Medical1.9903 of 5 stars$2.23-10.4%$9.00+303.6%+172.7%$77.48MN/A-2.7920Positive NewsGap UpSRTSSensus Healthcare2.3666 of 5 stars$4.45-3.1%$13.00+192.1%+42.7%$73.40M$41.81M11.1340 Related Companies and Tools Related Companies Lucid Diagnostics Competitors Orchestra BioMed Competitors InfuSystem Competitors KORU Medical Systems Competitors Beauty Health Competitors Monogram Orthopaedics Competitors iCAD Competitors InspireMD Competitors Microbot Medical Competitors Sensus Healthcare Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HSAQ) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Health Sciences Acquisitions Co. 2 Please log in to your account or sign up in order to add this asset to your watchlist. Share Health Sciences Acquisitions Co. 2 With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
